Related stories
Rapid Micro Biosystems Misses Q3 Revenue Estimates, Withdraws FY Outlook
Rapid Micro Biosystems reported Q3 revenue below estimates and withdrew its fiscal-year outlook.
M impact | EQUITY | Nov 16, 2026, 02:37 PM UTC
Johnson & Johnson Plans to Buy Ollin Biosciences for Up to $3.4 Billion
Media reports say Johnson & Johnson is planning to acquire privately held Ollin Biosciences, an Austin-based developer of eye-disease therapies, for up to $3.4 billion.
M impact | MNA | Nov 16, 2026, 02:36 PM UTC
Rapid Micro Biosystems Agrees to Be Acquired by Merck KGaA
Rapid Micro Biosystems says it signed a definitive acquisition agreement with Merck KGaA.
M impact | MNA | Nov 16, 2026, 02:32 PM UTC
Apollo Agrees to Invest in Focus Financial Partners
Apollo Global Management has agreed to provide financing to Focus Financial Partners.
M impact | MNA | Nov 16, 2026, 02:31 PM UTC
Rapid Micro Biosystems to Be Acquired by Merck KGaA
Rapid Micro Biosystems signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
M impact | MNA | Nov 16, 2026, 02:27 PM UTC
Ollin Biosciences Enters Definitive Agreement to Be Bought by Johnson & Johnson
Innovent Biologics says Ollin Biosciences has entered a definitive agreement to be acquired by Johnson & Johnson.
M impact | MNA | Nov 16, 2026, 02:26 PM UTC